CNTNAP2 and autoimmune hemolytic anemia: In autoimmune haemolytic anaemia (53), anti-phospholipid syndrome (54), treatment-refractory autoimmune cytopenias, cold agglutinin disease, and other autoimmune diseases (ITP, systemic lupus, anti-CASPR2 encephalitis, rheumatoid arthritis, ANCA-associated vasculitis) daratumumab has shown high efficacy in case series (55–57).